American Academy of Neurology Annual Meeting (AAN)

The neurologist at the University of Oklahoma Medical Center highlighted early diagnosis, prevention of secondary injury, and multimodal monitoring as key to improving patient outcomes in TBI. [WATCH TIME: 5 minutes]

At AAN 2026, an associate professor of neurology at University of Washington discussed how delays in antiamyloid treatment initiation for early Alzheimer disease may be driven by real-world factors. [WATCH TIME: 5 minutes]

In the phase 3 NIMBLE trial, Cemdisiran met primary and secondary endpoints, demonstrating rapid and sustained improvements in MG-ADL and QMG scores with once-every-12-week dosing in AChR-positive generalized myasthenia gravis.

Edith Graham, MD, assistant professor of neurology at Northwestern Feinberg School of Medicine, discussed diagnostic challenges and induction therapy outcomes in primary CNS vasculitis.

A phase 1b/2 trial presented at AAN 2026 showed HS-10506, a selective OX2R antagonist, significantly improved sleep latency and overall sleep outcomes in adults with insomnia.

A medical student at at Santa Casa de São Paulo School of Medical Sciences discussed the findings from a systematic review suggest potential biomarker-level benefits of estradiol-based hormone therapy in Alzheimer disease, but cautions that heterogeneous data limit firm conclusions. [WATCH TIME: 3 minutes]

New findings from a post hoc analysis of 2 phase 3 trials, presented at AAN 2026, reported that a majority of participants with advanced Parkinson disease had no troublesome dyskinesia at follow-up.

In the global phase 3 PREVAIL trial, gefurulimab met primary and secondary endpoints in adults with acetylcholine receptor antibody–positive generalized myasthenia gravis, potentially offering a more convenient alternative to intravenous therapies.

The president at Cala Health discussed the clinical role, evidence base, and potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.

New findings presented at AAN 2025 showed that treatment with satralizumab was associated with a reduction in annualized relapse rate compared with placebo over 48 weeks in patients with MOGAD.

Data show ofatumumab maintains a steady safety profile in relapsing MS, with low serious infections, stable labs, and durable biomarker improvements.

The professor of neurology at Mayo Clinic Rochester discussed why earlier detection of environmental risk in Parkinson disease remains difficult and how gene-environment research may help move the field forward. [WATCH TIME: 4 minutes]

In a 58-week open-label extension, most patients with Parkinson disease treated with tavapadon avoided starting levodopa or required no dose increases, suggesting a potential levodopa-sparing effect.

A phase 3, double-blind study is assessing telitacicept in generalized myasthenia gravis, following prior trials that demonstrated substantial improvements in functional and strength-based clinical outcomes.

Data from the phase 2 Vibrance-1 trial showed that alixorexton was associated with improvements in patient-reported outcomes in adults with narcolepsy type 1 over up to 12 to 13 weeks of follow-up.

A living systematic review presented at AAN 2026 showed that GLP-1 receptor agonists demonstrated biomarker and real-world signals of neuroprotection in Alzheimer disease.

Jaime Imitola, MD, FAAN, FANA, professor of neurology and director of the UConn Comprehensive MS Center, discussed validation data on VISIBL-MS and its role in improving early MS recognition.

The senior global medical director at Sanofi discussed the ongoing burden of CIDP, highlighting diagnostic challenges, treatment gaps, and the need for improved biomarkers and emerging therapies. [WATCH TIME: 3 minutes]

Semaglutide shows CNS biomarker shifts in early Alzheimer disease, lowering CSF tau and neurogranin while reshaping immune signals, as per new AAN data report.

Week-52 data from the phase 3 MINT trial show sustained improvements in MG-ADL and QMG scores with inebilizumab in patients with AChR-positive generalized myasthenia gravis.

Phase 2/3 LIBRA trial design evaluates basimglurant, an mGluR5 modulator, using a randomized withdrawal approach to assess durability of pain control and safety in adults with trigeminal neuralgia.

Phase 3 EPIC trial design highlights NRTX-1001 cell therapy as a potential single-administration approach to achieving durable seizure reduction in drug-resistant MTLE.

A recently presented analysis at AAN 2026 reported comparable safety and tolerability between atogepant and erenumab, with atogepant demonstrating a greater likelihood of early response at 1 month in adults with migraine.

Phase 3 data presented at AAN 2026 show fremanezumab significantly reduces monthly migraine days in pediatric episodic migraine but not chronic migraine.

Real-world data of the ELEVATE-PD study, presented at AAN 2026, suggest that switching to IPX203 from other levodopa-based therapies may improve motor function in patients with Parkinson disease.

Paul George, MD, PhD, FAAN, a board member of the American Academy of Neurology (AAN), gave an inside look at what clinicians can expect from the upcoming AAN Annual Meeting, held April 18-22 in Chicago.

Recently reported phase 2b results revealed that PrimeC consistently altered ALS-related miRNA expression, reinforcing its potential as a multi-targeted therapy and aligning with previously reported clinical benefits.

Josh Bryson, PhD, head of Medical Affairs at Argenx, discussed the safety profile of efgartigimod in light of recent FAERS-based infection data and offered clinical context for patient care.

The assistant professor of neurology at Robert Wood Johnson Medical School discussed the mission of RCASIA, highlights from its annual retreat, and key takeaways from AAN 2025.

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]